This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Prolonged Regression With Mitotane Therapy

Joseph Jarabak, MD, PhD; Kathryn Rice, MD

JAMA. 1981;246(15):1706-1707.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

CURRENTLY, there is a disagreement concerning the effectiveness of mitotane (o,p'-DDD) (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]-ethane) in the therapy for metastatic adrenal cortical carcinoma. Following the initial favorable report,¹ measurable tumor response was observed in two large series in 34 %² and 61 %³ of patients treated with this drug, and overall survival was prolonged when compared with an earlier group of untreated persons whose mean survival was 2.9 months. However, in another series,⁴ survival was not improved.

The following case is presented to illustrate a long-term remission of adrenocortical carcinoma and the effects that have been associated with the ingestion of more than 13 kg of mitotane.

Report of a Case

A 49-year-old woman was admitted to a hospital in November 1967 with hirsutism and masses in the left breast and abdomen. Roentgenograms disclosed metastases in the ribs and liver and downward displacement of the left kidney. Two 24-hour urine collections . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, the University of Chicago (Dr Jarabak), and the University of Minnesota, Minneapolis (Dr Rice).

Footnotes
Reprint requests to Department of Medicine, University of Chicago, 950 E 59th St, Chicago, IL 60637 (Dr Jarabak).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?